Literature DB >> 15306687

Nuclear cloning of embryonal carcinoma cells.

Robert H Blelloch1, Konrad Hochedlinger, Yasuhiro Yamada, Cameron Brennan, Minjung Kim, Beatrice Mintz, Lynda Chin, Rudolf Jaenisch.   

Abstract

Embryonal carcinoma (EC) cells have served as a model to study the relationship between cancer and cellular differentiation given their potential to produce tumors and, to varying degrees, participate in embryonic development. Here, nuclear transplantation was used to assess the extent to which the tumorigenic and developmental potential of EC cells is governed by epigenetic as opposed to genetic alterations. Nuclei from three independent mouse EC cell lines (F9, P19, and METT-1) with differing developmental and tumorigenic potentials all were able to direct early embryo development, producing morphologically normal blastocysts that gave rise to nuclear transfer (NT)-derived embryonic stem (ES) cell lines at a high efficiency. However, when tested for tumor or chimera formation, the resulting NT ES cells displayed an identical potential as their respective donor EC cells, in stark contrast to previously reported NT ES cells derived from transfer of untransformed cells. Consistent with this finding, comparative genomic hybridization identified previously undescribed genetic lesions in the EC cell lines. Therefore, nonreprogrammable genetic modifications within EC nuclei define the developmental and tumorigenic potential of resulting NT ES cells. Our findings support the notion that cancer results from the deregulation of stem cells and further suggest that the genetics of ECs will reveal genes involved in stem cell self-renewal and pluripotency.

Entities:  

Mesh:

Year:  2004        PMID: 15306687      PMCID: PMC521109          DOI: 10.1073/pnas.0405015101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Differentiation of embryonic stem cell lines generated from adult somatic cells by nuclear transfer.

Authors:  T Wakayama; V Tabar; I Rodriguez; A C Perry; L Studer; P Mombaerts
Journal:  Science       Date:  2001-04-27       Impact factor: 47.728

2.  Chromosomal silencing and localization are mediated by different domains of Xist RNA.

Authors:  Anton Wutz; Theodore P Rasmussen; Rudolf Jaenisch
Journal:  Nat Genet       Date:  2002-01-07       Impact factor: 38.330

Review 3.  From teratocarcinomas to embryonic stem cells.

Authors:  Peter W Andrews
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

Review 4.  Gene silencing in cancer in association with promoter hypermethylation.

Authors:  James G Herman; Stephen B Baylin
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

5.  Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy.

Authors:  William M Rideout; Konrad Hochedlinger; Michael Kyba; George Q Daley; Rudolf Jaenisch
Journal:  Cell       Date:  2002-04-05       Impact factor: 41.582

Review 6.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

7.  Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice.

Authors:  S E Artandi; S Chang; S L Lee; S Alson; G J Gottlieb; L Chin; R A DePinho
Journal:  Nature       Date:  2000-08-10       Impact factor: 49.962

8.  Hybrid vigor, fetal overgrowth, and viability of mice derived by nuclear cloning and tetraploid embryo complementation.

Authors:  K Eggan; H Akutsu; J Loring; L Jackson-Grusby; M Klemm; W M Rideout; R Yanagimachi; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

9.  Monoclonal mice generated by nuclear transfer from mature B and T donor cells.

Authors:  Konrad Hochedlinger; Rudolf Jaenisch
Journal:  Nature       Date:  2002-02-10       Impact factor: 49.962

10.  METT-1: a karyotypically normal in vitro line of developmentally totipotent mouse teratocarcinoma cells.

Authors:  B Mintz; C Cronmiller
Journal:  Somatic Cell Genet       Date:  1981-07
View more
  54 in total

1.  Biography of Rudolf Jaenisch.

Authors:  Christen Brownlee
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

2.  DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal.

Authors:  Yangming Wang; Rostislav Medvid; Collin Melton; Rudolf Jaenisch; Robert Blelloch
Journal:  Nat Genet       Date:  2007-01-28       Impact factor: 38.330

Review 3.  Epigenetic reprogramming and induced pluripotency.

Authors:  Konrad Hochedlinger; Kathrin Plath
Journal:  Development       Date:  2009-02       Impact factor: 6.868

4.  G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells.

Authors:  Lijun Liu; Wojciech Michowski; Hiroyuki Inuzuka; Kouhei Shimizu; Naoe Taira Nihira; Joel M Chick; Na Li; Yan Geng; Alice Y Meng; Alban Ordureau; Aleksandra Kołodziejczyk; Keith L Ligon; Roderick T Bronson; Kornelia Polyak; J Wade Harper; Steven P Gygi; Wenyi Wei; Piotr Sicinski
Journal:  Nat Cell Biol       Date:  2017-02-13       Impact factor: 28.824

5.  Efficiencies and mechanisms of nuclear reprogramming.

Authors:  V Pasque; K Miyamoto; J B Gurdon
Journal:  Cold Spring Harb Symp Quant Biol       Date:  2010-11-03

Review 6.  Nuclear transfer to eggs and oocytes.

Authors:  J B Gurdon; Ian Wilmut
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

Review 7.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

8.  microRNA-based cancer cell reprogramming technology.

Authors:  Shimpei Nishikawa; Hideshi Ishii; Naotsugu Haraguchi; Yoshihiro Kano; Takahito Fukusumi; Katsuya Ohta; Miyuki Ozaki; Dyah Laksmi Dewi; Daisuke Sakai; Taroh Satoh; Hiroaki Nagano; Yuichiro Doki; Masaki Mori
Journal:  Exp Ther Med       Date:  2012-04-23       Impact factor: 2.447

Review 9.  The molecular programme of tumour reversion: the steps beyond malignant transformation.

Authors:  Adam Telerman; Robert Amson
Journal:  Nat Rev Cancer       Date:  2009-01-30       Impact factor: 60.716

10.  MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors.

Authors:  Dvora Nass; Shai Rosenwald; Eti Meiri; Shlomit Gilad; Hilla Tabibian-Keissar; Anat Schlosberg; Hagit Kuker; Netta Sion-Vardy; Ana Tobar; Oleg Kharenko; Einat Sitbon; Gila Lithwick Yanai; Eran Elyakim; Hila Cholakh; Hadas Gibori; Yael Spector; Zvi Bentwich; Iris Barshack; Nitzan Rosenfeld
Journal:  Brain Pathol       Date:  2008-07-02       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.